Twist Bioscience Corporation (NASDAQ:TWST) reported Q2 EPS of ($1.13), $0.15 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $48.1 million versus...
Barclays (LON:BARC) analyst Luke Sergott maintained a Buy rating on Twist Bioscience (NASDAQ:TWST) Corp on Friday, setting a price target of $130, which is approximately 60.22%...
July was an excellent month for global stock marketsHistorically, the S&P 500 takes about 19 months to recover from a bear marketHowever, since 1982, if the bear market does...
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.